Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis.

MLA

Liu, Shi-Jia, et al. “Safety, Efficacy, and Survival Outcomes of Immune Checkpoint Inhibitors Rechallenge in Patients with Cancer: A Systematic Review and Meta-Analysis.” Oncologist, vol. 29, no. 11, Nov. 2024, pp. e1425–34. EBSCOhost, https://doi.org/10.1093/oncolo/oyae134.

APA

Liu, S.-J., Yan, L.-J., Wang, H.-C., Ding, Z.-N., Liu, H., Zhang, X., Pan, G.-Q., Han, C.-L., Tian, B.-W., Yang, X.-R., Tan, S.-Y., Dong, Z.-R., Wang, D.-X., Yan, Y.-C., & Li, T. (2024). Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis. Oncologist, 29(11), e1425–e1434. https://doi.org/10.1093/oncolo/oyae134

Chicago

Liu, Shi-Jia, Lun-Jie Yan, Han-Chao Wang, Zi-Niu Ding, Hui Liu, Xiao Zhang, Guo-Qiang Pan, et al. 2024. “Safety, Efficacy, and Survival Outcomes of Immune Checkpoint Inhibitors Rechallenge in Patients with Cancer: A Systematic Review and Meta-Analysis.” Oncologist 29 (11): e1425–34. doi:10.1093/oncolo/oyae134.